Gardasil
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Human Papillomavirus
Conditions
Human Papillomavirus
Trial Timeline
Feb 19, 2013 → Nov 3, 2020
NCT ID
NCT01432574About Gardasil
Gardasil is a phase 2 stage product being developed by Merck for Human Papillomavirus. The current trial status is completed. This product is registered under clinical trial identifier NCT01432574. Target conditions include Human Papillomavirus.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04022148 | Pre-clinical | UNKNOWN |
| NCT01432574 | Phase 2 | Completed |
| NCT01741012 | Phase 1 | Completed |
| NCT01338051 | Phase 1 | Completed |
| NCT00925288 | Approved | Completed |
| NCT01133509 | Pre-clinical | UNKNOWN |
| NCT00786409 | Pre-clinical | Completed |
| NCT00666107 | Pre-clinical | UNKNOWN |
Competing Products
20 competing products in Human Papillomavirus